FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET
On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients 12 years of age and older
Read More